(−)-Propranolol inhibits the behavioural responses of rats to increased 5-hydroxytryptamine in the central nervous system

Abstract

THERE are now several reports of the beneficial effect of large doses of (±)-propranolol in the treatment of various psychoses, particularly schizophrenia1–3. These reports prompted us to investigate whether propranolol had any effect on the behavioural syndrome produced in rats by increasing the functional activity of 5-hydroxytryptamine (5-HT) or dopamine (DA) in the central nervous system. Our results indicate that large doses of (−)-propranolol but not (+)-propranolol inhibit the behavioural responses resulting from increased functional activity of central 5-HT but not DA.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Atsmon, A., Blum, I., Wijsenbeek, H., Maoz, B., Steiner, M., and Ziegelman, G., Psychiat. Neurol. Neurochir., 74, 251–258 (1971).

  2. 2

    Atsmon, A., Blum, I., Steiner, M., and Wijsenbeek, H., Psychopharmacologia, 27, 249–254 (1972).

  3. 3

    Yorkston, N. J., Zaki, S. A., Malik, M. K. U., Morrison, R. C., and Havard, C. W. H., Br. med. J., 4, 633–635 (1974).

  4. 4

    Grahame-Smith, D. G., J. Neurochem., 18, 1053–1066 (1971).

  5. 5

    Green, A. R., and Grahame-Smith, D. G., Nature, 260, 487–491 (1976).

  6. 6

    Grahame-Smith, D. G., Br. J. Pharmac., 43, 856–864 (1971).

  7. 7

    Bradley, P. B., and Briggs, I., Br. J. Pharmac., 50, 345–354 (1974).

  8. 8

    Green, A. R., Hughes, J. P., and Tordoff, A. F. C., Neuropharmacology, 14, 601–606 (1974).

  9. 9

    Shand, D. G., Rango, R. E., and Evans, G. H., Pharmacology, 8, 344–352 (1972).

  10. 10

    Green, A. R., and Kelly, P. H., Br. J. Pharmac., 57, 141–147 (1976).

  11. 11

    Ungerstedt, U., Acta physiol. scand., 83, Suppl. 367, 49–68 (1971).

  12. 12

    Kelly, P. H., Brain Res., 100, 507–522 (1975).

  13. 13

    Clement-Cormier, Y. L., Kebabian, J. W., Petzold, G. L., and Greengard, P., Proc. natn. Acad. Sci. U.S.A., 71, 1113–1117 (1974).

  14. 14

    Scales, B., & Cosgrove, N. B., J. Pharmac. exp. Ther., 175, 338–347 (1970).

  15. 15

    Bainbridge, J. G., and Greenwood, D. T., Neuropharmacology, 10, 453–458 (1971)

  16. 16

    Weinstock, M., and Speiser, Z., Psychopharmacologia, 30, 241–250 (1973)

  17. 17

    Weinstock, M., and Schechter, Y., Eur. J. Pharmac., 32, 293–301 (1975)

  18. 18

    Miller, R. J., Horn, A. S., and Iversen, L. L., Molec. Pharmac., 10, 759–766 (1974).

  19. 19

    Iversen, L. L., Science, 188, 1084–1089 (1975).

  20. 20

    Heal, D. J., Green, A. R., Boullin, D. J., and Grahame-Smith, D. G., Psycho-pharmacologia (in the press).

  21. 21

    Green, A. R., and Grahame-Smith, D. G., Neuropharmacology, 13, 949–959 (1974).

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.